Migraine is typically characterized by recurring headaches, throbbing
pain on one side of the head along with one or more of the following symptoms:
nausea; vomiting; and increased sensitivity to light, sound and smell (Bigal
and Lipton, 2006). Because migraine is one of the most prevalent types of
headache, there is a substantial economic and social burden associated with the
condition worldwide, and it is therefore recognized as a high-priority public
health problem by the World Health Organization (WHO) (Leonardi et al., 2005;
Lusic, 2001). The Global Burden of Disease (GBD) study in 2010 ranks migraine
as the first among the neurological disorders (Leonardi and Raggi, 2013).
In 2023, Publisher epidemiologists forecast that the total prevalent
cases of migraine in the 7MM remained almost the same, with 75.83 million total
prevalent cases in 2013 and 76.38 million total prevalent cases, with an annual
growth rate (AGR) of 0.07% in the forecast period. Throughout the forecast
period, the US will have the highest number of total prevalent cases of
migraine, with 29.61 million total prevalent cases in 2013 and 31.13 million
total prevalent cases in 2023.
Publisher epidemiologists obtained total prevalence data for migraine
from peer-reviewed journals and population-based studies in the respective
markets and used consistent methodology to ensure comparability of results.
Furthermore, Publisher epidemiologists made a meaningful assumption that the
age- and sex-specific total prevalence of migraine in the 7MM would remain
constant throughout the forecast period because epidemiologic literature
suggests relatively stable trends in the prevalence of migraine worldwide,
thereby providing a realistic and meaningful forecast for the age- and
sex-specific total prevalent cases of migraine in the 7MM.
Scope
- The Migraine EpiCast Report provides an overview of the risk factors, comorbidities, and global trends of migraine in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the total prevalent cases of migraine segmented by age (beginning at 18 years and ending at 80 years and older), sex, and the number of total prevalent cases of migraine with aura and without aura in these markets.
- The migraine epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to buy
- Develop business strategies by understanding the trends shaping and driving the global migraine market.
- Quantify patient populations in the global migraine market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for migraine therapeutics in each of the markets covered.
- Identify the number of migraine cases with aura and without aura.
Spanning
over 44 pages, 10 Tables And 5 Figures “Migraine
- Epidemiology Forecast to 2023” report provide Epidemiology, Disease
Background, Risk Factors and Comorbidities, Forecast Methodology, Appendix.
Inquiry for more information
visit:
Find All Medical
Devices Reports at:
For regular industry updates subscribe to our newsletter at:
No comments:
Post a Comment
Note: only a member of this blog may post a comment.